AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 31823527
Drug: 1.25 mg
RxNorm normalized name: menthol 1.25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.25 mg rasagiline transdermal patch (48-hour patch-on period)
Trial: 31823527
Drug: 2.5 mg
RxNorm normalized name: biotin 2.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.5 mg rasagiline transdermal patch (48-hour patch-on period)
Trial: 31823527
Drug: 1 mg
RxNorm normalized name: biotin 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg rasagiline tablet (repeated doses for 7 days)
Trial: 31823527
Drug: 1.25 mg
RxNorm normalized name: menthol 1.25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.25 mg rasagiline transdermal patch (repeated doses every 72 hours for 5 time periods)
Trial: 28436727
Drug: Polypill-based treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Polypill-based treatment (aspirin 75 mg, simvastatin 40 mg, lisinopril 10 mg and either atenolol 50 mg or hydrochlorothiazide 12.5 mg)
Trial: 28436727
Drug: Polypill-based treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Polypill-based treatment
Trial: 23526462
Drug: Intralipid (IL)
DrugBank: Soybean oil (DB09422)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intralipid (IL) infusion
Trial: 21470450
Drug: Intensive hand
RxNorm normalized name: ALCOHOL 350 mL in 500 mL TOPICAL GEL [CLEAN UP Intensive Hand Sanitizer Gel]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensive hand hygiene campaign (washing hands twice each day and health messages through entertainment activities)
Trial: 16857049
Drug: Chronic Disease
RxNorm normalized name: Chromic Chloride
DrugBank: Chromic chloride (DB09129)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Chronic Disease Self‐Management Program (CDSMP) consisting of six weekly sessions led by a CHF nurse specialist and a CHF patient.
Trial: 7572943
Drug: Galvin insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Galvin insulin sensitivity measure (calculated from FSIGT)
Trial: 29025835
Drug: CML-enhanced maternal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CML-enhanced maternal milk formulation
Trial: 29025835
Drug: Standard maternal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard maternal milk formulation
Trial: 21481024
Drug: Oral desensitization
RxNorm normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral desensitization
Trial: 17000686
Drug: Abagovomab 2.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Abagovomab 2.0 mg
Trial: 17000686
Drug: Abagovomab 0.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Abagovomab 0.2 mg
Trial: 12566890
Drug: Latanoprost additive
RxNorm normalized name: Latanoprost
DrugBank: Latanoprost (DB00654)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Latanoprost additive therapy
Trial: 9701293
Drug: 1 mg
RxNorm normalized name: biotin 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg dihydroergotamine (DHE)
Trial: 9701293
Drug: 1.5 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.5 mg/kg meperidine (MEP)
Trial: 7981460
Drug: Droloxifene (pooled
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Droloxifene (pooled 40 + 100 mg)
Trial: 2657320
Drug: Pulsatile Insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pulsatile Insulin (PI) - 75% of 32 mU/kg/h delivered as 40-second pulses every 13 minutes
Trial: 2657320
Drug: Continuous Insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Continuous Insulin (CI) - 32 mU/kg/h continuous infusion
Trial: 2657320
Drug: Continuous Insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Continuous Insulin (CI) - second 12 CI infusions
Trial: 2657320
Drug: Pulsatile Insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pulsatile Insulin (PI) followed by Continuous Insulin (CI)
Trial: 2657320
Drug: Continuous Insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Continuous Insulin (CI) followed by Continuous Insulin (CI)
Trial: 2657320
Drug: Pulsatile Insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pulsatile Insulin (PI) - first infusion
Trial: 2657320
Drug: Continuous Insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Continuous Insulin (CI) - first infusion
Trial: 29030478
Drug: Early statin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Early statin therapy within 24 hours after admission
Trial: 29030478
Drug: Delayed statin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Delayed statin therapy on the seventh day after admission
Trial: 29030478
Drug: Delayed statin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Delayed statin therapy
Trial: 24260889
Drug: Intraoperative radiation
RxNorm normalized name: allantoin
DrugBank: Allantoin (DB11100)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intraoperative radiation therapy (IORT) with 15 Gy, preoperative chemotherapy with paclitaxel/carboplatin, and radiosensitization with cisplatin
Trial: 19291011
Drug: Pegylated interferon
RxNorm normalized name: Pegylated interferon alfa-2a
DrugBank: Peginterferon alfa-2a (DB00008)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pegylated interferon alpha-2a + ribavirin 800 mg/day (Group A)
Trial: 19291011
Drug: Pegylated interferon
RxNorm normalized name: Pegylated interferon alfa-2a
DrugBank: Peginterferon alfa-2a (DB00008)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pegylated interferon alpha-2a + ribavirin 400 mg/day (Group B)
Trial: 10955697
Drug: Cetirizine (antihistamine)
RxNorm normalized name: Ahist Antihistamine
DrugBank: Cetirizine (DB00341)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cetirizine (antihistamine)
Trial: 8846524
Drug: Individualized heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Individualized heparin dosing protocol with a loading dose of 50 u/kg and continuous infusion of 15 u/kg/h, adjusted with a sliding scale to target WBAPPT in the range of 150-190 seconds.
Trial: 6568354
Drug: Group 1
RxNorm normalized name: Chlamydophila psittaci biogroup 1 Ab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group 1 - monthly measurements and reinforcement of behavioral, diet, and exercise components
Trial: 6568354
Drug: Group 2
RxNorm normalized name: Chlamydophila psittaci biogroup 2 Ab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group 2 - monthly measurements
Trial: 31648401
Drug: Autoimplantation technique
RxNorm normalized name: zinc pyrithione
DrugBank: Pyrithione (DB06815)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Autoimplantation technique every 2 weeks for a maximum of four treatments
Trial: 31648401
Drug: MMR intralesional
RxNorm normalized name: varicella-zoster virus vaccine live (Oka-Merck) strain
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MMR intralesional injection at a dose of 0.5 ml every 2 weeks for a maximum of four treatments
Trial: 31648401
Drug: MMR intralesional
RxNorm normalized name: varicella-zoster virus vaccine live (Oka-Merck) strain
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MMR intralesional injection
Trial: 28816894
Drug: Operative treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Operative treatment (ORIF)
Trial: 23742058
Drug: Dilute wood
RxNorm normalized name: Wood creosote
DrugBank: Wood creosote (DB13271)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dilute wood smoke exposure (mean particle concentration of 314±38 μg/m3)
Trial: 21284478
Drug: Insulin glargine
RxNorm normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Insulin glargine at 60% of TDI
Trial: 21284478
Drug: Insulin glargine
RxNorm normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Insulin glargine at 80% of TDI
Trial: 21284478
Drug: Insulin glargine
RxNorm normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Insulin glargine based on TDI and body weight
Trial: 15514265
Drug: Pinitol supplementation
RxNorm normalized name: Fomitopsis pinicola fruiting body extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pinitol supplementation (2000 mg/day)
Trial: 9228438
Drug: Statin drugs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Statin drugs
Trial: 3305461
Drug: Ceftazidime sodium
RxNorm normalized name: Ceftazidime Sodium
DrugBank: Ceftazidime (DB00438)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ceftazidime sodium (1 or 2 g intramuscular injections, three times daily)
Trial: 3305461
Drug: Ceftazidime arginine
RxNorm normalized name: Ceftazidime
DrugBank: Ceftazidime (DB00438)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ceftazidime arginine (1 or 2 g intramuscular injections, three times daily)
Trial: 3305461
Drug: Ceftazidime sodium
RxNorm normalized name: Ceftazidime Sodium
DrugBank: Ceftazidime (DB00438)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ceftazidime sodium (1 g injections)
Trial: 3305461
Drug: Ceftazidime arginine
RxNorm normalized name: Ceftazidime
DrugBank: Ceftazidime (DB00438)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ceftazidime arginine (1 g injections)
Trial: 3305461
Drug: Ceftazidime sodium
RxNorm normalized name: Ceftazidime Sodium
DrugBank: Ceftazidime (DB00438)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ceftazidime sodium (2 g injections)
Trial: 3305461
Drug: Ceftazidime arginine
RxNorm normalized name: Ceftazidime
DrugBank: Ceftazidime (DB00438)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ceftazidime arginine (2 g injections)
Trial: 31914105
Drug: Peer specialist
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Peer specialist services (community-based, structured curriculum for recovery, up to 40 weekly sessions)
Trial: 31914105
Drug: Treatment as
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment as usual (case management services)
Trial: 16886198
Drug: Rapid intravenous
RxNorm normalized name: Abreva Rapid Pain Relief
DrugBank: Glycerin (DB09462)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rapid intravenous infusion
Trial: 14644862
Drug: Glucocorticoid treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glucocorticoid treatment (prednisone)
Trial: 10903217
Drug: Losartan (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Losartan (50 mg once a day)
Trial: 1891610
Drug: Patient-controlled antiemetic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patient-controlled antiemetic therapy (PCAE)
Trial: 1891610
Drug: Nurse-administered antiemetic
RxNorm normalized name: metoclopramide
DrugBank: Metoclopramide (DB01233)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nurse-administered antiemetic therapy (NCAE)
Trial: 6150491
Drug: 6 mg
RxNorm normalized name: boron 6 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 mg bromazepam daily for 3 weeks
Trial: 6150491
Drug: Placebo daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo daily for 3 weeks
Trial: 2908134
Drug: 6 mg
RxNorm normalized name: boron 6 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 mg bromazepam
Trial: 30747551
Drug: Hydrothermally modified
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydrothermally modified corn starch (HMS) ingestion (8% carbohydrate containing a total of 0.7 g·kg BM‐1·hr‐1; 2.8 kcal·kg BM‐1·hr‐1)
Trial: 29502050
Drug: Ultrasound-guided hormone
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ultrasound-guided hormone injection
Trial: 27138575
Drug: Letrozole (2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Letrozole (2.5 mg orally per day) plus Bevacizumab (15 mg/kg intravenously once every 3 weeks)
Trial: 30509771
Drug: Letrozole (2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Letrozole (2.5 mg orally per day)
Trial: 21750975
Drug: Vibration Therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vibration Therapy (VT) - 5 sets of 1 min at 26 Hz, 6 mm peak-to-peak displacement
Trial: 21750975
Drug: Control treatment
RxNorm normalized name: SALICYLIC ACID 190 mg in 1 mL TOPICAL LIQUID [Derma E Acne Blemish Control Treatment Serum]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control treatment (no VT)
Trial: 20555372
Drug: ARGININE (3.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ARGININE (3.0 g of arginine, 300 mg of grape seed extract, and 300 mg of polyethylene glycol)
Trial: 18278836
Drug: Etanercept (ETN)
RxNorm normalized name: Etanercept
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Etanercept (ETN) therapy
Trial: 18278836
Drug: Placebo (PLA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (PLA) followed by Etanercept (ETN) therapy
Trial: 16029070
Drug: NXY-059 (disufenton
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NXY-059 (disufenton sodium) continuous intravenous infusion for 72 hours, including a 1-hour loading infusion
Trial: 3171790
Drug: Dhaka solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dhaka solution with dextrose (DS + D)
Trial: 3171790
Drug: Dhaka solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dhaka solution without dextrose (DS)
Trial: 26106114
Drug: Intensive therapy
RxNorm normalized name: Cortaid Intensive Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensive therapy (16 hours per week for 3 weeks)
Trial: 26106114
Drug: Distributed therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Distributed therapy (6 hours per week for 8 weeks)
Trial: 17875958
Drug: Hyperuricemia (serum
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hyperuricemia (serum uric acid level, >7.0 mg/dL)
Trial: 14759231
Drug: Comparators (levofloxacin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comparators (levofloxacin 500 mg once daily, clarithromycin 500 mg twice daily, amoxicillin/clavulanate 875/125 mg, and 1000/125 mg)
Trial: 7868986
Drug: Oral estradiol,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral estradiol, 2 mg daily
Trial: 7868986
Drug: Transdermal estradiol,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdermal estradiol, 0.1 mg twice weekly
Trial: 3336615
Drug: Ankle suspension
RxNorm normalized name: Bos taurus ankle joint preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ankle suspension method
Trial: 3336615
Drug: Thigh suspension
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thigh suspension method
Trial: 3336615
Drug: Both methods
RxNorm normalized name: Bothrops atrox venom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both methods (ankle and thigh suspension)
Trial: 22692502
Drug: Lysozyme-specific IgE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lysozyme-specific IgE level higher than 7 kU/L
Trial: 21658562
Drug: CRT-D therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CRT-D therapy (high responders)
Trial: 21658562
Drug: CRT-D therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CRT-D therapy (low responders)
Trial: 16684435
Drug: Prednicarbate ointment
RxNorm normalized name: Prednicarbate Ointment
DrugBank: Prednicarbate (DB01130)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Prednicarbate ointment (Group 3)
Trial: 15230485
Drug: Isoflavones (90
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isoflavones (90 mg daily for 6 weeks)
Trial: 30109588
Drug: Huannao Yicong
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Huannao Yicong Formula (HYF) 5 g granules twice daily
Trial: 24372674
Drug: 0.2 mg
RxNorm normalized name: niacin 0.2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.2 mg tamsulosin once a day
Trial: 15361892
Drug: Nonstatin antihyperlipidaemic
RxNorm normalized name: Nystatin
DrugBank: Nystatin (DB00646)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nonstatin antihyperlipidaemic drug
Trial: 15361892
Drug: All four
RxNorm normalized name: Jackson's The Original All Fours
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All four antihyperlipidaemic drugs
Trial: 11882512
Drug: Intravenous dideuterated
RxNorm normalized name: Deuterated water
DrugBank: Deuterium oxide (DB19251)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous dideuterated Delta(5)-phytosterols and oral pentadeuterated Delta(5)-phytosterols
Trial: 11882512
Drug: 600 mg
RxNorm normalized name: mesna 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600 mg of soy stanols
Trial: 10572324
Drug: Fluoxetine (20-60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoxetine (20-60 mg)
Trial: 6403172
Drug: Inhalation of
RxNorm normalized name: Ocean brand of sodium chloride Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhalation of ultrasonically nebulised distilled water
Trial: 29365017
Drug: Endovascular treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endovascular treatment (successful reperfusion)
Trial: 29365017
Drug: Endovascular treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endovascular treatment (successful recanalization)
Trial: 26778346
Drug: Waiting, treatment,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Waiting, treatment, and travel time
Trial: 26778346
Drug: Treatment scheme
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment scheme
Trial: 25088843
Drug: Intravenous thrombolysis
RxNorm normalized name: thrombocytin
DrugBank: Serotonin (DB08839)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous thrombolysis with alteplase at 0.6 mg/kg body weight
Trial: 334500
Drug: Low-dose heparin
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose heparin (5000 IU daily, twice)
Trial: 334500
Drug: Combined heparin
RxNorm normalized name: heparin, combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined heparin and dihydroergotamine (5000 IU heparin and 0.5 mg dihydroergotamine daily)
Trial: 28657801
Drug: 20mg melatonin
RxNorm normalized name: melatonin 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20mg melatonin gargle before each irradiation and 20mg melatonin capsules nightly during 7 weeks of concurrent chemoradiation
Trial: 26281607
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose group (112 patients) for acute diarrhea
Trial: 26281607
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose group (113 patients) for acute diarrhea
Trial: 26281607
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose group (56 patients) for chronic persistent diarrhea
Trial: 26281607
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose group (55 patients) for chronic persistent diarrhea
Trial: 22254076
Drug: Folic acid
RxNorm normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Folic acid 140 µg/day
Trial: 19929183
Drug: Physical Activity
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physical Activity on Prescription (PAP) programme with exercise twice a week, education, and motivational counselling
Trial: 19929183
Drug: Physical Activity
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physical Activity on Prescription (PAP) programme
Trial: 12717237
Drug: Rabbit antithymocyte
RxNorm normalized name: Rabbit antithymocyte globulin
DrugBank: Antithymocyte immunoglobulin (rabbit) (DB00098)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rabbit antithymocyte globulin (RATG) 1.5 mg/kg during the anhepatic phase followed by 1.5 mg/kg on posttransplant day 1
Trial: 12717237
Drug: Methylprednisolone 1,000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methylprednisolone 1,000 mg followed by a 3-month steroid taper
Trial: 8304789
Drug: 2.5 g
RxNorm normalized name: Vaporizer 2.5 gallon
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.5 g dipyrone combined with a spasmolytic agent and 30 mg ketorolac tromethamine
Trial: 2878600
Drug: Bevantolol 150
RxNorm normalized name: bevantolol
DrugBank: Bevantolol (DB01295)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bevantolol 150 mg twice daily
Trial: 28139557
Drug: Trimetazidine 35
RxNorm normalized name: trimetazidine 35 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trimetazidine 35 mg twice daily
Trial: 28139557
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of bisoprolol 1.25‐2.5 mg once daily and ivabradine 2.5‐7.5 mg twice daily
Trial: 22212127
Drug: Tdap vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tdap vaccine (Boostrix(®))
Trial: 20159247
Drug: Intravenous montelukast
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous montelukast 7 mg
Trial: 16278987
Drug: Phenylalanine-free essential
RxNorm normalized name: Phenylalanine
DrugBank: Phenylalanine (DB00120)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Phenylalanine-free essential amino acid tablets (AA tablets)